IMV Researchers to Present New Preclinical Data at AACR Annual Meeting 2019

On March 12, 2019 IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical stage immuno-oncology company reported that members of the Company’s research and development team will present results from a study at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting 2019, which is being held March 29 to April 3 in Atlanta, Georgia (Press release, IMV, MAR 12, 2019, View Source [SID1234534242]). The new preclinical research highlights the unique features of DPX-based T cell immunotherapies.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"The unique capabilities of our DPX-based platform and its potential to fuel novel treatment approaches continue to drive IMV’s robust research and development program"

Tweet this
"The unique capabilities of our DPX-based platform and its potential to fuel novel treatment approaches continue to drive IMV’s robust research and development program," said Marianne Stanford, PhD, Vice President, Research and Development of IMV. "We are looking forward to presenting additional insights into the way our platform works, and its capacity for working with other anti-cancer agents, at this year’s AACR (Free AACR Whitepaper) annual meeting. This work supports our goal of expanding the benefits of immunotherapies to a wider range of patients and indications."

Details of IMV’s AACR (Free AACR Whitepaper) 2019 poster is as follows:

Session Category: Immunology
Abstract Number: 4989
Authors: Ava Vila-Leahey, Alecia MacKay, Genevieve Weir, Marianne Stanford

Title: T-distributed stochastic neighbor embedding (t-SNE) analysis of tumor infiltrating lymphocytes after treatment with a T cell activating therapy identifies a unique population of recruited CD8+ T cells and novel options for combination immunotherapy

Date: Wednesday Apr 3, 2019
Time: 8:00 a.m. – 12:00 p.m. ET
Location: Georgia World Congress Center, Exhibit Hall B, Poster Section 24
Poster Board Number: 12

Meeting abstracts are available at AACR (Free AACR Whitepaper)’s website.